Insulet Corporation Promotes Luis Malave to Chief Operating Officer

Feb 15, 2007

Insulet Corporation Promotes Luis Malave to Chief Operating Officer

Insulet Corporation Promotes Luis Malave to Chief Operating Officer

BEDFORD, Mass., February 15, 2007 – Insulet Corporation announced today that Luis Malavé has been promoted to the position of Chief Operating Officer. Since 2002, Mr. Malavé has served as the company's Senior Vice President of Research, Development & Engineering. In his new role, Mr. Malavé will be responsible for the day-to-day operations of the company, including manufacturing, research and development, and quality and regulatory affairs. Insulet Corporation is the developer and manufacturer of the OmniPod® Insulin Management System, an innovative product for the treatment of diabetes that brings together safe, reliable, continuous subcutaneous insulin infusion and blood glucose monitoring in a discreet and easy-to-use, two-part system.

With more than 20 years of experience in the medical device industry, Mr. Malavé spent six years in senior-level positions with Medtronic MiniMed in Northridge, California prior to joining Insulet. During his tenure there, he was responsible for a broad range of market-impacting projects including the development of several insulin pump systems.

“Luis has proven to be a tremendous asset in the development of our OmniPod System and an integral part of our management team,” said Duane DeSisto, Insulet President and CEO. “The expertise that he brings to the position of COO will be invaluable to helping us expand our market reach and achieve our business goals.”

Mr. Malavé earned Bachelors degrees in Mathematics and Computer Science from the University of Minnesota, a Masters degree in Software Engineering from the University of St. Thomas, and an MBA from the University of Maryland. He and his family live in Reading, Massachusetts.

About Insulet Corporation

Founded in 2000, Insulet Corporation is a privately-held medical device company located in Bedford, Massachusetts. The companyseeks to improve the lives of people with diabetes and expand the use of continuous subcutaneous insulin infusion (CSII) therapy through innovative technology and feedback from people with diabetes and healthcare professionals. Insulet Corporation develops, manufactures and markets the OmniPod Insulin Management System, an innovative, discreet and easy-to-use insulin infusion system for people with insulin-dependent diabetes.

For more information about Insulet Corporation and the OmniPod System, please visit our website at